Drug Database
ES

escitalopram + clonazepam (Citapure Forte)

✓ Approved

A. N. Pharmacia Laboratories · GABRA1 · 小分子

什么是 escitalopram + clonazepam?

escitalopram + clonazepam 是一种小分子,由A. N. Pharmacia Laboratories研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Citapure Forte
公司A. N. Pharmacia Laboratories
药物类别小分子
分子靶点GABRA1, GABRA2, GABRA3, GABRA4, SLC6A4
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

escitalopram + clonazepam 作用于 5 个分子靶点:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (ECA4, EJM)
GABRA2gamma-aminobutyric acid type A receptor alpha2 subunit (EIEE78, DEE78)
GABRA3gamma-aminobutyric acid type A receptor alpha3 subunit (EPILX2)
GABRA4gamma-aminobutyric acid type A receptor alpha4 subunit ()
SLC6A4solute carrier family 6 member 4 (SERT1, 5-HTTLPR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

escitalopram + clonazepam 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersBipolar I disorder✓ Approved
Psychiatric disordersGeneralised anxiety disorder✓ Approved

相关研究文献

PubMedBMJ open2026-11-18

Efficacy and safety of Idebenone Combined with Escitalopram in Patients with Post-stroke Depression (IDBPSD): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial in China.

Luan Heya H, Wang Xin X, Shan Aidi A, Han Xiaodong X et al.

PMID 43051637
阅读全文 →
PubMedAmerican heart journal2026-11-18

Selective serotonin reuptake inhibitors And Depression in Atrial Fibrillation: Design of the SAD-AF Randomized Controlled Trial.

Koh Y Y, Lu L L, Chen L L, Das S K SK et al.

Atrial fibrillation and depression are frequently comorbid, with autonomic dysfunction as a potential shared underlying pathophysiology. However, the effect of the treatment of depression on atrial fibrillation has not been well characterized, despite previous investigation of selective serotonin reuptake inhibitors into other forms of cardiovascular disease such as coronary artery disease. To test whether escitalopram, a selective serotonin reuptake inhibitor, reduces AF-related symptoms, AF burden and AF presentations to hospital compared to placebo, in addition to standard of care. Multicenter, randomized, single-blind, parallel-group superiority trial. Eligible participants are aged 18-80 years with paroxysmal or persistent atrial fibrillation, with the goal of rhythm control, who also score 8 or more on the PHQ-9 questionnaire (out of a maximum score of 27). 154 patients will be randomized to escitalopram or placebo in doses of 5mg to 20mg, titrated to individual patient response. The primary outcome is the Atrial Fibrillation Effect on Quality of Life (AFEQT) score. Secondary outcomes include AF burden, adherence to lifestyle risk factor management including self-rated physical activity index (EPIC-PAQ-S questionnaire), general quality of life (SF-36 questionnaire), and hospital presentations for atrial fibrillation. Rhythm monitoring for AF burden will be undertaken with either mobile single lead ECG monitoring (Alivecor Kardiamobile), ECG-capable smartwatch, Holter monitoring or interrogation of pre-existing cardiac electronic implantable device. Autonomic metrics will be assessed by non-invasive recordings of blood pressure and heart rate variability. The study aims to determine the impact of managing AF with a selective serotonin reuptake inhibitor, with a patient-centered primary outcome.

PMID 43051387
阅读全文 →
PubMedJA clinical reports2026-11-18

Perioperative transient myoclonic state with asterixis in an elderly patient: a case report.

Kurosawa Shin S, Kameyama Eri E, Kobayashi Michiko M, Handa Kyoichi K et al.

Transient myoclonic state with asterixis (TMA) is characterized by repetitive, short-lived myoclonus without impaired consciousness disturbance. Herein, we report a case of an elderly man who developed TMA perioperatively. A man in his 80 s who was independent in activities of daily living underwent lumbar laminectomy under general anesthesia. Post-operatively, he emerged from anesthesia without any issues including neurological symptoms. On the night of postoperative day (POD) 1, he remained conscious, but developed acute dysarthria, finger tremor, and involuntary tremulous movements involving the face, neck, tongue, and bilateral upper extremities. Routine laboratory investigations and brain magnetic resonance imaging showed no abnormalities. He was diagnosed with TMA and responded well to oral clonazepam. TMA should be recognized in the differential diagnosis of acute onset involuntary movements, particularly in patients after general anesthesia. Increased awareness of this condition is important to avoid misdiagnosis and unnecessary interventions and ensure appropriate management.

PMID 43045916
阅读全文 →
PubMedBrain, behavior, and immunity2026-11-18

Choroid plexus enlargement in unmedicated major depressive disorder inflammation, oxidative stress and treatment outcome.

Jensen K H R KHR, Alakhir Safia S, Köhler-Forsberg Kristin K, Falk Kalle K et al.

The choroid plexus has emerged as a putative neuroimmune interface implicated in major depressive disorder (MDD). Choroid plexus enlargement has been reported across several MDD cohorts, yet its relationship with peripheral inflammation, oxidative stress, and antidepressant treatment response remains unresolved. We used data from NeuroPharm-1, an open-label trial of escitalopram in 96 unmedicated patients with moderate-to-severe MDD and 84 healthy controls (HC) aged 18 to 57 years. Choroid plexus volume (CPV) was measured using deep-learning-based segmentation of T1-weighted MRI. Peripheral inflammation was indexed by high-sensitivity C-Reactive Protein (hsCRP), and oxidative stress by urinary 8-oxodG and 8-oxoGuo. Group differences in CPV were examined using a general linear model controlling for age, sex, BMI, and total intracranial volume. Associations with inflammation, oxidative stress, and treatment effects over 12 weeks were assessed in secondary and exploratory analyses. Analyses were preregistered at AsPredicted.org (ID 270379) RESULTS: Patients showed larger CPV than HC (β = 194 mm3 [9, 378], p = 0.040; Hedges' g = 0.32). However, pretreatment CPV was not associated with depression severity (HAMD17), hsCRP, or oxidative stress. Pretreatment CPV did not predict symptom trajectory over 12 weeks. CPV remained stable from baseline to week 8, with no significant change (p = 0.452). This study replicates CPV enlargement in unmedicated MDD, strengthening evidence that it is a feature of the disorder. CPV was unrelated to peripheral inflammatory and oxidative stress markers, suggesting cumulative blood-CSF barrier reactivity rather than concurrent circulating inflammation. CPV did not decrease with treatment, suggesting high short-term stability.

PMID 43051383
阅读全文 →
PubMedFrontiers in pharmacology2026-11-17

Comparative efficacy and safety of nonhormonal prescription drugs for vasomotor symptoms in women with breast cancer: a systematic review and network meta-analysis.

Liao Yin-Sheng YS, Deng Yu-Ping YP, Song Jian-Li JL, Yu Xuan X et al.

Vasomotor symptoms (VMS) are common during and after breast cancer treatment, particularly among women receiving endocrine therapy. We compared the efficacy, acceptability, and safety of nonhormonal prescription pharmacological interventions for VMS in women with breast cancer or breast cancer survivors. We searched major databases and trial registries through July 2026 for randomized controlled trials comparing nonhormonal prescription drugs versus placebo or another eligible nonhormonal prescription drug in adult women with breast cancer-related VMS. The primary outcome was continuous VMS efficacy. Secondary outcomes included responder outcomes, all-cause discontinuation, discontinuation due to adverse events, any adverse events, and serious adverse events. We performed frequentist random-effects network meta-analysis, with Bayesian network meta-analysis as sensitivity analysis. Risk of bias was assessed using RoB 2, and certainty of evidence using a GRADE/NMA-GRADE approach. Eighteen publications, corresponding to 19 study/substudy records and 2,224 randomized or allocated participants, were included. Five interventions were significantly more effective than placebo: escitalopram (SMD -1.08, 95% CI -1.80 to -0.37), desvenlafaxine 50 mg (SMD -0.87, 95% CI -1.60 to -0.15), desvenlafaxine 100 mg (SMD -0.80, 95% CI -1.44 to -0.15), elinzanetant (SMD -0.51, 95% CI -0.95 to -0.07), and venlafaxine 75 mg (SMD -0.42, 95% CI -0.76 to -0.07). Heterogeneity was moderate (I2 = 44.9%), with no significant global or local inconsistency. Frequentist P-scores ranked the five significant drugs top, confirmed by Bayesian sensitivity. Elinzanetant had high-certainty evidence, whereas venlafaxine 75 mg and gabapentin 900 mg had moderate-certainty evidence. Escitalopram and desvenlafaxine had large effects, but the supporting evidence was sparse. Discontinuation outcomes showed no statistically significant differences versus placebo, but sparse safety networks precluded a reliable comparative safety hierarchy; these null findings should not be interpreted as evidence of equivalent tolerability. Nonhormonal prescription drugs are not interchangeable for breast cancer-related VMS. Elinzanetant provides the strongest high-certainty evidence among newer targeted options, and venlafaxine 75 mg is the best-supported conventional option. Escitalopram and desvenlafaxine remain promising but require further trials. Gabapentin 900 mg may be considered in selected patients, whereas sertraline, bupropion, gabapentin 300 mg, and clonidine are lower-priority options. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261460108, identifier CRD420261460108.

PMID 43041301
阅读全文 →
PubMedActa neurologica Belgica2026-11-17

Acute multifocal myoclonus as a rare central nervous system manifestation of propoxur (carbamate) poisoning.

Tayade Kamalesh K

Carbamates cause reversible acetylcholinesterase (AChE) inhibition producing a cholinergic toxidrome similar to organophosphate poisoning. Myoclonus is an exceedingly rare CNS complication, with very few indexed cases reported. A 24-year-old male presented four hours after intentional ingestion of ~ 30 mL of 100% propoxur, with bradycardia, hypotension, miosis, and garlic-like breath odour. Pseudocholinesterase was critically suppressed (< 200 U/L). After intubation and atropinisation, he developed sudden multifocal, arrhythmic, non-stimulus-sensitive myoclonic jerks within six hours of ingestion - earlier than the typical post-hypoxic window. EEG showed mild slowing without epileptiform discharges; MRI was normal. Lance-Adams syndrome, post-hypoxic myoclonus, seizures, hypoxic-ischaemic encephalopathy, and metabolic causes were systematically excluded. With clonazepam, myoclonus resolved within 24-48 h; the patient was discharged neurologically intact. This case documents unusually early-onset multifocal myoclonus in propoxur poisoning, expanding the sparse carbamate-specific literature and illustrating a structured exclusion approach in a resource-limited setting.

PMID 43043615
阅读全文 →

注册免费账户还可查看另外 8365 篇文献

免费注册查看全部文献 →

了解更多escitalopram + clonazepam